Studi Literatur: Penggunaan Obat Remdesivir dan Favipiravir dalam Terapi Covid-19

  • Sri Lestari Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
  • Dewi Mayasari Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
  • Yurika Sastyarina Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia

Abstract

Coronavirus Disease 2019 (COVID-19) is a respiratory disease caused by the new coronavirus and is spreading rapidly throughout the world. Several studies were conducted to find these antiviral agents, one of which is Remdesivir and Favipiravir. This literature study aims to examine the use of Remdesivir and Favipiravir as therapy in COVID-19 patients with a literature study. The research method used is a literature review with an electronic database of indexed journals with a journal publication time limit for 2019-2020 using the appropriate keywords. From the 10 literature that has been reviewed, it shows that the use of Remdesivir and Favipiravir in the treatment of COVID-19 provides an improvement in the patient's health condition.

Author Biographies

Sri Lestari, Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
Dewi Mayasari, Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
Yurika Sastyarina, Laboratorium Penelitian dan Pengembangan Kefarmasian "Farmaka Tropis", Fakultas Farmasi, Universitas Mulawarman, Samarinda, Kalimantan Timur, Indonesia
Published
2020-12-16
How to Cite
Lestari, S., Mayasari, D., & Sastyarina, Y. (2020). Studi Literatur: Penggunaan Obat Remdesivir dan Favipiravir dalam Terapi Covid-19. Proceeding of Mulawarman Pharmaceuticals Conferences, 12(1), 197-201. https://doi.org/10.25026/mpc.v12i1.425

Most read articles by the same author(s)